Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling

References

• LiSZhuangZWuTNicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancerRedox Biol20181824625530059901
   PubMed Web of Science ®Google Scholar
• JemalABrayFCenterMMGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• ChangPWangFLiYHsa_circ_0000673 is down-regulated in gastric cancer and inhibits the proliferation and invasion of tumor cells by targeting miR-532-5pBiosci Rep2018BSR2018053830061181
   PubMed Web of Science ®Google Scholar
• TursunBSchlüterAPetersMAThe ubiquitin ligase Rnf6 regulates local LIM kinase 1 levels in axonal growth conesGenes Dev200519192307231916204183
   PubMed Web of Science ®Google Scholar
• LoHSHuNGereSIdentification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinomaCancer Res200262154191419312154016
   PubMed Web of Science ®Google Scholar
• LiuLZhangYWongCCRNF6 Promotes Colorectal Cancer by Activating the Wnt/β-Catenin Pathway via Ubiquitination of TLE3Cancer Res20187881958197129374067
   PubMed Web of Science ®Google Scholar
• LiangQMaDZhuXRING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal CancerClin Cancer Res20182461473148529288235
   PubMed Web of Science ®Google Scholar
• XuXHanKTangXThe Ring Finger Protein RNF6 Induces Leukemia Cell Proliferation as a Direct Target of Pre-B-cell Leukemia Homeobox 1J Biol Chem2016291189617962826971355
   PubMed Web of Science ®Google Scholar
• ZengYXuXWangSRing finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alphaOncotarget2017812201032011228223545
   PubMedGoogle Scholar
• XuKShimelisHLinnDERegulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitinationCancer Cell200915427028219345326
   PubMed Web of Science ®Google Scholar
• XuXWangJHanKAntimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cellsCancer Sci201810941220122929453896
   PubMed Web of Science ®Google Scholar
• XuXZhangJHanKNatural pesticide dihydrorotenone arrests human plasma cancer cells at the G0/G1 phase of the cell cycleJ Biochem Mol Toxicol201428523223824615755
   PubMed Web of Science ®Google Scholar
• HanKXuXChenGIdentification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimizationJ Hematol Oncol20147924428908
   PubMed Web of Science ®Google Scholar
• ChenGXuXTongJUbiquitination of the transcription factor c-MAF is mediated by multiple lysine residuesInt J Biochem Cell Biol20145715716625448412
   PubMed Web of Science ®Google Scholar
• HanKXuXXuZSC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathwaySci Rep201551280926329846
   PubMed Web of Science ®Google Scholar
• XuXHanKZhuJAn inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathwayOncotarget2016746755397555027705908
   PubMedGoogle Scholar
• JiZPQiangLZhangJLTranscription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancerExp Ther Med20181521831183829434772
   PubMed Web of Science ®Google Scholar
• KangXLiMZhuHDUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transitionOncotarget2017855940289403929212207
   PubMedGoogle Scholar
• XuJLiuDNiuHResveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancerJ Exp Clin Cancer Res20173611928126034
   PubMed Web of Science ®Google Scholar
• HanYAminHMFrankoBLoss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphomaBlood200610882796280316825495
   PubMed Web of Science ®Google Scholar
• MorrowJKLinHKSunSCZhangSTargeting ubiquitination for cancer therapiesFuture Med Chem20157172333235026630263
   PubMed Web of Science ®Google Scholar
• HuangZWuYZhouXEfficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trialsFuture Oncol201410101795180725303058
   PubMed Web of Science ®Google Scholar
• Wallington-BeddoeCTSobieraj-TeagueMKussBJPitsonSMResistance to proteasome inhibitors and other targeted therapies in myelomaBr J Haematol20181821112829676460
   PubMed Web of Science ®Google Scholar
• FarshiPDeshmukhRRNwankwoJODeubiquitinases (DUBs) and DUB inhibitors: a patent reviewExpert Opin Ther Pat201525101191120826077642
   PubMed Web of Science ®Google Scholar
• MalekEAbdel-MalekMAJagannathanSPharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myelomaLeukemia201731364565327677741
   PubMed Web of Science ®Google Scholar
• LuQHeYWangYSaponins From Paris forrestii (Takht.) H Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling PathwayFront Pharmacol2018967329997504
   PubMed Web of Science ®Google Scholar
• CafferkeyCChauINovel STAT 3 inhibitors for treating gastric cancerExpert Opin Investig Drugs201625910231031
   PubMed Web of Science ®Google Scholar
• TongMWangJJiangNPanHLiDCorrelation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysisPLoS One2017128e018228228797050
   PubMed Web of Science ®Google Scholar
• JohnsonDEO’KeefeRAGrandisJRTargeting the IL-6/JAK/STAT3 signalling axis in cancerNat Rev Clin Oncol201815423424829405201
   PubMed Web of Science ®Google Scholar
• KitamuraHOhnoYToyoshimaYInterleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapyCancer Sci2017108101947195228749573
   PubMed Web of Science ®Google Scholar
• VanklompenbergMKLeydenEArnasonAHAPC loss in breast cancer leads to doxorubicin resistance via STAT3 activationOncotarget201786110286810287929262529
   PubMedGoogle Scholar
• ZhangZLJiangQCWangSRSchisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylationBreast Cancer201825223324229181822
   PubMed Web of Science ®Google Scholar